To remain viable, Warrington-based Windtree Therapeutics plans on boosting revenue by acquiring smaller companies with FDA-approved products, writes John George for the Philadelphia Business Journal.

One of the region’s oldest biotechnology companies will pursue this new corporate strategy of all-stock deals while advancing its internal drug candidates for heart disease and cancer.

“We believe that Windtree becoming a revenue-generating company would be a significantly positive transformation and would mark a new chapter in our growth story,” said Jed Latkin, CEO of Windtree.

“By pursuing this strategy, we maintain our commitment to advance our promising cardiovascular and oncology pipeline, while simultaneously leveraging our deep commercialization expertise to accelerate revenue growth through strategic acquisitions.”

The new approach will make it possible for the company to create near-term value by acquiring commercial operations while also preserving its development programs.

Windtree plans on targeting small biotech companies that may be struggling to fully capitalize on the commercialization potential of their FDA-approved products. According to the company, its management team has commercialization expertise in biotech companies in multiple therapeutic areas.

Windtree will use equity for the acquisitions, with the number of deals depending on the valuation and growth potential of the target companies.

Read more about Windtree Therapeutics’ plans to boost revenue by acquiring smaller companies in the Philadelphia Business Journal.